I'm Back! Trying hard to continue to be succesful Investing/trading in Biotechnology, no matter how hard the obstacles, or setbacks(at times)!
South USA
Joined August 2025
- Tweets1.5K
- Following49
- Followers134
- Likes4.6K
$NTLA Getting slaughtered today, down 10% on Low(always) volume, near lows of the year, for the 10th time or so. Guess cures in the US of A aren't as valuable like they used to be.
Toss all your money into Space companies that can take you to Mars, or into Cars that can flip over the moon going down the road, valued at a Trillion Valuation or more!.....lol.
What a brainless market!
".......a one-time gene editing infusion cut hereditary angioedema attacks 87%, and 62% of patients stayed attack-free and off all other prevention for 6 months...."
this might be my last normal tweet before biotech goes vertical
i'm not a whistleblower. I don't work at Lilly, Novo or any of the big labs
but there is a massive shift happening in human biology right now.
it's sitting in press releases and almost nobody reads them
the last 6 months alone:
- a once-daily pill roughly doubled median survival in metastatic pancreatic cancer (13.2 vs 6.6 months)
- a one-time gene editing infusion cut hereditary angioedema attacks 87%, and 62% of patients stayed attack-free and off all other prevention for 6 months
- a one-time gene edit for cholesterol dropped LDL up to 62%, and it held for over a year
- a personalized mrna vaccine beat keytruda alone in a 1,137 patient melanoma phase 3
- retatrutide hit ~28% weight loss in a phase 3
- an ai-designed drug entered phase 3
- a pill that regrows hair passed its second phase 3
- an immunotherapy that could let some rectal cancer patients skip surgery, chemo and radiation just got fda approved
- a man lived 271 days off dialysis on a pig kidney
- human cells were caught passing chromosome-sized chunks of DNA to their neighbors, and it changes how the neighbors behave
we are on the verge of an era where the human body is a software problem and the update cycle gets shorter everyday
stick around, it's going to get weird
bio/acc
AnExpertOne retweeted
1/🚨WOW! Intellia announced the completion of enrollment in its MAGNITUDE-2 Phase 3 clinical trial aimed to evaluate nex-z in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). Nex-z - formerly known as $NTLA - 2001, is Intellia’s In Vivo CRISPR-based clinical candidate designed to inactivate the TTR gene in the liver, thus preventing the production of transthyretin (TTR) protein which is the root cause for hereditary transthyretin amyloidosis.
ALT WOW! Intellia announced the completion of enrollment in its MAGNITUDE-2 Phase 3 clinical trial aimed to evaluate nex-z in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). Nex-z - formerly known as NTLA - 2001, is Intellia’s In Vivo CRISPR-based clinical candidate designed to inactivate the TTR gene in the liver, thus preventing the production of transthyretin (TTR) protein which is the root cause for hereditary transthyretin amyloidosis.
4/Nex-z delivers sgRNA & Cas9 into the nucleus. This allows to precisely edit the TTR gene thus inactivating it. Once inactivated-it prevents the production of the TTR protein. To simplify - by pulling out the plug you prevent electricity thus preventing the TV from working $NTLA
ALT Nex-z delivers sgRNA & Cas9 into the nucleus. This allows to precisely edit the TTR gene thus inactivating it. Once inactivated-it prevents the production of the TTR protein. To simplify - by pulling out the plug you prevent electricity thus preventing the TV from working
LibertyStream Announces Lithium Carbonate Sales Contract with International Battery Material Maker Covering 2027–2031 Supply
$LIB.v $VLTLF
businesswire.com/news/home/2…
$PGEN Just bought more - absolute stupidity selling this low, but some moron is still stacking the ask. Maybe to toss more funds into AI to replace their own brains?
AnExpertOne retweeted
Here we go, what we were waiting for so long!
Up to 17500 tonne deal! $LIB.v $VLTLF
LibertyStream Announces Lithium Carbonate Sales Contract with International Battery Material Maker Covering 2027–2031 Supply
businesswire.com/news/home/2…
AnExpertOne retweeted
$PGEN PAPZIMEOS® net revenue rose 37% quarter-over-quarter to $72.9 million in the third quarter of 2026 bringing launch-to-date net product revenue to $151 million, underscoring sustained commercial momentum and expanding US adoption
Achieved positive cash flow in the third quarter of 2026, a full quarter ahead of guidance, driven by robust PAPZIMEOS uptake
Net income for the third quarter of $35.8 million
Cash, cash equivalents, and investments totaled $51.0 million as of September 30, 2026
Received FDA Platform Technology Designation for the AdenoVerse® platform, creating opportunities to expedite development of current and future therapies
New long-term follow-up data presented at AAO-HNSF 2026 demonstrated ongoing durable complete responses after PAPZIMEOS treatment for up to five years
Conference call scheduled for 4:30 PM ET today
$QURE This is so stupid ~ nutty haters would have tried to knock it down today, irregardless.....
*uniQure N.V. QURE.OQ reported a quarterly adjusted loss of 88 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.38. The mean expectation of twelve analysts for the quarter was for a loss of 92 cents per share. Wall Street expected results to range from $-1.22 to -74 cents per share.
THEY BEAT THE MEAN!.....ha! At least the volume is fairly low,..... always the case, it seems.
******************************
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for uniQure N.V. is $54.50, about 56.2% above its last closing price of $23.87
AnExpertOne retweeted
📢 $NTLA News: We’re excited to share Intellia has completed enrollment in MAGNITUDE-2, our Phase 3 trial investigating the one-time treatment of patients with #ATTR #amyloidosis with polyneuropathy. Read the press release: ir.intelliatx.com/news-relea…
They will have to raise funds soon! (Better sell that pop?)>
$INO Inovio’s management estimates that its current cash, cash equivalents, and short-term investments will fund operations into late first quarter 2027. This projected timeline carries the company directly through the initial commercial launch of its newly approved RRP therapy, Voceryq.
Yep, no threat to Precigen $PGEN anytime soon.
And $PGEN did shockingly hit $5 & under - hard to believe! But much better position than INO < they can't even collect(most likely) desperately needed funds from a positive lawsuit outcome for a lot of money!....lol. (Party sued has very little funds available -likely outcome for INO in a year)
*Why Precigen Dominates the Baseline Case
*The "J-Code" Moat: Precigen's permanent J-code streamlines the reimbursement workflow for clinics. Doctors hate billing friction. Inovio's Voceryq will initially face a 6-to-12-month period of using unclassified billing codes, which can delay reimbursement approvals and cause clinics to hesitate to stock the drug.
*Superior Data on Paper: In independent, non-head-to-head trials, PAPZIMEOS demonstrated a significantly higher surgery-free rate (51% vs. Voceryq’s 27%). Most physicians will naturally default to the drug with the higher statistical efficacy when managing severe cases.
Hard to believe $PGEN down to near $6 - would be awesome if it hit near $5! But not going to hold my breath for that. RSI is already at 35 unseen since June, but slight chance it could move a bit lower. NOV ER finances should look good with another beat, and for sure after INO news hits, stock should fly....imo.
AnExpertOne retweeted
$QURE’s platform franchise era has officially begun. A 1 of 1 HD asset and more to come. Stay tuned.
Beaten up enough already! $QURE should be flying up on the news. RSI only in the 30s - definitely not overbought.
Eventually.
We are thrilled to announce that the FDA has accepted for review the BLA for ifezuntirgene inilparvovec (AMT-130), an investigational #genetherapy for #HuntingtonsDisease. The application has been granted Priority Review with a PDUFA date of May 1, 2027. uniqure.gcs-web.com/news-rel…
AnExpertOne retweeted
$QURE plz note this is with Priority Review!! 😃😃 there will b adcom BUT this will will finally b where 4 year amt-130 patients can finally speak out about the treatment - how they’re happy to b alive & functioning vs bedridden ,dependent on other or dead
UniQure $QURE announces FDA acceptance and Priority Review of BLA for AMT-130 for treatment of Huntington's disease
PDUFA May 1, 2027
"In its acceptance letter, the FDA stated that they are tentatively planning to discuss this application at an Advisory Committee meeting. The Company will be notified once the date and timelines have been finalized."